Toleranzia AB
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
TOL | ST
Overview
Corporate Details
- ISIN(s):
- SE0007438577 (+1 more)
- LEI:
- 529900ARVN1D3A4CHI81
- Country:
- Sweden
- Address:
- Arvid Wallgrens backe 20, 413 46 Göteborg
- Website:
- https://www.toleranzia.se/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Toleranzia AB is a biotechnology company developing therapies that utilize the immune system to treat rare autoimmune (orphan) diseases. The company's approach focuses on targeting the underlying cause of a disease, aiming to create curative or long-acting treatments that go beyond symptom management. Its lead drug candidate, TOL2, is in development for the treatment of the neuromuscular disease myasthenia gravis (MG). Toleranzia's pipeline also includes TOL3, a candidate for the treatment of the autoimmune blood vessel disease ANCA-vasculitis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Toleranzia AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Toleranzia AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-04 | Thomas Eldered | Other | Sell | 12,000,000 | 5,100,000.00 SEK |
| 2025-04-03 | Thomas Eldered | Other | Sell | 23,764,705 | 10,099,999.62 SEK |
